============
Convatec Group PLC (CTEC)
Convatec Group PLC: Scrip Dividend - Total Issued Shares
13-Sep-2023 / 16:50 GMT/BST
══════════════════════════════════════════════════════════════════════════
13 September 2023
Convatec Group Plc
("Convatec" or "the Company")
Scrip Dividend - Total Issued Shares
The Board of Directors of Convatec declared an interim dividend in respect
of 2023 of 1.769 cents per share ("Interim Dividend"). The Interim
Dividend is to be paid on 28 September 2023 to shareholders on the share
register as at 18 August 2023 ("Record Date"). The dividend is payable in
cash in sterling to holders of ordinary shares. On 2 August 2023, the
Company announced that a scrip dividend would be made available for the
Interim Dividend, allowing shareholders to elect to receive their dividend
in the form of new ordinary shares. The calculation price for the scrip
dividend was announced on 25 August 2023.
It is confirmed that 4,199,962 new ordinary shares of 10 pence each will
be allotted and issued on 28 September 2023 by the Company to those
shareholders who elected to receive the scrip dividend alternative. The
shares will rank pari passu with the existing issued ordinary shares of
the Company. Application will be made to the Financial Conduct Authority
for the shares to be admitted to the Official List and to the London Stock
Exchange for the shares to be admitted to trading.
Following the issue of shares under the scrip dividend scheme in respect
of the Interim Dividend, the Company's issued share capital will be
2,049,789,559 ordinary shares of 10 pence each. Dealings in the shares
issued under the scrip dividend scheme are expected to commence on 28
September 2023.
Details of the scrip dividend scheme are available at
1 www.convatecgroup.com/investors.
Enquiries
Kate Postans, VP Investor
Relations +44 (0)782 644 7807
ir@convatec.com
Convatec Group Plc’s LEI code is 213800LS272L4FIDOH92
About Convatec
Pioneering trusted medical solutions to improve the lives we touch:
Convatec is a global medical products and technologies company, focused on
solutions for the management of chronic conditions, with leading positions
in advanced wound care, ostomy care, continence care and infusion care.
With around 10,000 colleagues, we provide our products and services in
almost 100 countries, united by a promise to be forever caring. Our
solutions provide a range of benefits, from infection prevention and
protection of at-risk skin, to improved patient outcomes and reduced care
costs. Group revenues in 2022 were over $2 billion. The company is a
constituent of the FTSE 100 Index (LSE: CTEC). To learn more about
Convatec, please visit 2 www.convatecgroup.com.
══════════════════════════════════════════════════════════════════════════
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
══════════════════════════════════════════════════════════════════════════
ISIN: GB00BD3VFW73
Category Code: TVR
TIDM: CTEC
LEI Code: 213800LS272L4FIDOH92
Sequence No.: 271279
EQS News ID: 1725687
End of Announcement EQS News Service
══════════════════════════════════════════════════════════════════════════
3 fncls.ssp?fn=show_t_gif&application_id=1725687&application_name=news&site_id=refinitiv
References
Visible links
1. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=cd503027e07da3a35980bba88dbdb093&application_id=1725687&site_id=refinitiv&application_name=news
2. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=26f8de477e9a42123589f91471356e0b&application_id=1725687&site_id=refinitiv&application_name=news
============